BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8844397)

  • 1. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions.
    Deppert W
    J Cell Biochem; 1996 Aug; 62(2):172-80. PubMed ID: 8844397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
    Deppert W; Göhler T; Koga H; Kim E
    J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.
    Will K; Warnecke G; Wiesmüller L; Deppert W
    Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13681-6. PubMed ID: 9811860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.
    Koga H; Deppert W
    Oncogene; 2000 Aug; 19(36):4178-83. PubMed ID: 10962580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics and Molecular Mechanisms of p53 Transcriptional Activation.
    Offutt TL; Ieong PU; Demir Ö; Amaro RE
    Biochemistry; 2018 Nov; 57(46):6528-6537. PubMed ID: 30388364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High affinity MAR-DNA binding is a common property of murine and human mutant p53.
    Will K; Warnecke G; Albrechtsen N; Boulikas T; Deppert W
    J Cell Biochem; 1998 Jun; 69(3):260-70. PubMed ID: 9581865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation.
    Raveh T; Droguett G; Horwitz MS; DePinho RA; Kimchi A
    Nat Cell Biol; 2001 Jan; 3(1):1-7. PubMed ID: 11146619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.
    Frum RA; Love IM; Damle PK; Mukhopadhyay ND; Palit Deb S; Deb S; Grossman SR
    Mol Cancer Res; 2016 May; 14(5):423-36. PubMed ID: 26965143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
    Loging WT; Reisman D
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.